Lyon, France, July 6, 2022 – 6:00 p.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French late-stage biotechnology company, a pioneer in the development of drugs in the restoration of the intestinal microbiota to improve the survival of patients with cancer, announces the availability of its universal registration document for the financial year ended December 31, 2021, filed with the Autorité des Marchés Financiers (AMF) on July 5, 2022 under visa number R.22-032.
For any additional information, you can send an e-mail to [email protected].